ArticleCancer research2019
4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 81 citations in OpenAlex.
- A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Inhibition of PI3K/AKT/mTOR pathway suppresses growth of oral squamous cell carcinoma in 2D and 3D in vitro model and animal model.Genes & genomics · 2026Article
- From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies.Endocrine · 2026Review
- The 4E-BP1 deletion modestly mitigates mTORC1-deficient epidermal barrier defects.JID innovations : skin science from molecules to population health · 2026Article
- Sweet apple e-cigarette vapor differentially modulates the mTOR pathway in oral squamous cell carcinoma cell lines.Frontiers in oncology · 2026Article
- Loss of the translational repressor 4E-BP1 promotes skin carcinogenesis.Frontiers in pharmacology · 2026Article
- Reactivation of the PI3K/mTOR Signaling Pathway Confers Resistance to the FGFR4 Inhibitor FGF401.International journal of molecular sciences · 2025Article
- Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer.Cancer research · 2025Article
- The EIF4EBP1 gene encoding 4EBP1 is transcriptionally upregulated by MYC and linked to shorter survival in medulloblastoma.Cell death discovery · 2025Article
- Article
- The eIF3a translational control axis in the Wnt/β-catenin signaling pathway and colon tumorigenesis.Cancer letters · 2024Article
- A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance.Nature cancer · 2024Article
- A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC.Cancer research communications · 2024Article
- mTORC1 regulates cell survival under glucose starvation through 4EBP1/2-mediated translational reprogramming of fatty acid metabolism.Nature communications · 2024Article
- A Multifunctional Bimetallic Nanoplatform for Synergic Local Hyperthermia and Chemotherapy Targeting HER2-Positive Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- VAV2 orchestrates the interplay between regenerative proliferation and ribogenesis in both keratinocytes and oral squamous cell carcinoma.Scientific reports · 2024Article
- Auranofin and reactive oxygen species inhibit protein synthesis and regulate the level of the PLK1 protein in Ewing sarcoma cells.Frontiers in oncology · 2024Article
- High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma.Cell reports. Medicine · 2023Article
- Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.Cancer research · 2023Article
- Combined Gadolinium and Boron Neutron Capture Therapies for Eradication of Head-and-Neck Tumor Using GdJACS Au · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 4 countries.
Zhiyong WangMoores Cancer Center, University of California, San Diego, La Jolla, California.ORCID 0000-0002-3574-6078
Xiaodong FengMoores Cancer Center, University of California, San Diego, La Jolla, California.
Alfredo A MolinoloMoores Cancer Center, University of California, San Diego, La Jolla, California.ORCID 0000-0001-8412-2889
Daniel MartinNational Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-8880-9087
Lynn Vitale-CrossNational Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-7850-547X
Nijiro NohataMoores Cancer Center, University of California, San Diego, La Jolla, California.ORCID 0000-0002-6816-2984
Mizuo AndoMoores Cancer Center, University of California, San Diego, La Jolla, California.
Amy WahbaNational Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Panomwat AmornphimolthamMoores Cancer Center, University of California, San Diego, La Jolla, California.
Xingyu WuMoores Cancer Center, University of California, San Diego, La Jolla, California.
Mara GilardiMoores Cancer Center, University of California, San Diego, La Jolla, California.
Michael AllevatoMoores Cancer Center, University of California, San Diego, La Jolla, California.
Victoria WuMoores Cancer Center, University of California, San Diego, La Jolla, California.
Dana J SteffenMoores Cancer Center, University of California, San Diego, La Jolla, California.
Philip TofilonNational Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Nahum SonenbergDepartment of Biochemistry and Goodman Cancer Centre, McGill University, Montreal, Quebec, Canada.ORCID 0000-0002-4707-8759
Joseph CalifanoMoores Cancer Center, University of California, San Diego, La Jolla, California.
Qianming ChenState Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China. sgutkind@ucsd.edu slippman@ucsd.edu qmchen@scu.edu.cn.
Scott M LippmanMoores Cancer Center, University of California, San Diego, La Jolla, California. sgutkind@ucsd.edu slippman@ucsd.edu qmchen@scu.edu.cn.
J Silvio GutkindMoores Cancer Center, University of California, San Diego, La Jolla, California. sgutkind@ucsd.edu slippman@ucsd.edu qmchen@scu.edu.cn.
University of California San Diego · USNational Institute of Dental and Craniofacial Research · USNational Institutes of Health · USSichuan University · CNMcGill University Health Centre · CA
Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9MGRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5MRadiation-induced translational control of gene expressionZIABC011373 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TOFILON, PHILIP · 2011 to 2025
$11.7MTargeting Signaling Vulnerabilities for Oral Cancer PreventionR01DE026644 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jorge Silvio Gutkind, SCOTT M LIPPMAN · 2017 to 2026
$4.7MTargeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision TherapyR01DE026870 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUTKIND, JORGE SILVIO · 2018 to 2022
$2.3MArea C: Genome-wide identification and targeting of resistance to cancer therapyR33CA225291 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI GUTKIND, JORGE SILVIO, RUPPIN, EYTAN · 2017 to 2017
$1.5MNCI NIH HHS P30 CA023100NCI NIH HHS R33 CA225291NIDCR NIH HHS R01 DE026644NIDCR NIH HHS R01 DE026870NIGMS NIH HHS T32 GM007752
Abstract
Aberrant activation of the PI3K-mTOR signaling pathway occurs in >80% of head and neck squamous cell carcinomas (HNSCC), and overreliance on this signaling circuit may in turn represent a cancer-specific vulnerability that can be exploited therapeutically. mTOR inhibitors (mTORi) promote tumor regression in genetically defined and chemically induced HNSCC animal models, and encouraging results have been recently reported. However, the mTOR-regulated targets contributing to the clinical response have not yet been identified. Here, we focused on
Indexed as
Adaptor Proteins, Signal TransducingAdenineAnimalsBenzoxazolesBiomarkers, TumorCell Cycle ProteinsCell Line, TumorCell ProliferationCRISPR-Cas SystemsHead and Neck NeoplasmsHumansMiceMice, KnockoutPhosphorylationPrognosisPyrimidinesAdaptor Proteins, Signal TransducingAdenineBenzoxazolesBiomarkers, TumorCell Cycle ProteinsEIF4EBP1 protein, humanMTOR protein, humanPyrimidinessapanisertibTOR Serine-Threonine KinasesTumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.